<DOC>
	<DOCNO>NCT01319929</DOCNO>
	<brief_summary>To investigate safety , efficacy pharmacokinetics single daily oral dose LY2828360 male female subject osteoarthritic knee pain</brief_summary>
	<brief_title>A Study LY2828360 Patients With Osteoarthritic Knee Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Are male female patient osteoarthritis ( OA ) , determine medical history physical examination . Males females stable medical problem , investigator 's opinion , significantly alter disposition drug , place patient increase risk participate study , interfere interpretation data . 1 . Male patient : agree use reliable method birth control study 3 month follow last dose investigational product 2 . Female patient : woman childbearing potential due surgical sterilization ( least 6 week post surgical bilateral oophorectomy without hysterectomy tubal ligation ) confirm medical history , menopause Body weight great 40 kilogram ( kg ) less 120 kilogram ( kg ) body mass index ( BMI ) 1935 kilogram per square meter ( kg/m^2 ) inclusive Patient osteoarthritic knee base disease diagnostic criterion present Inclusion Disease Criteria , Blood pressure pulse rate supine stand position , within normal reference range population investigator clinical research unit ( CRU ) , result acceptable deviation judge clinically significant investigator Have clinical laboratory test result within normal reference range population investigator clinical research unit ( CRU ) , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample Have agree maintain activity level throughout course study Inclusion Disease Criteria : Have unilateral bilateral osteoarthritis ( OA ) knee diagnose accord American College Rheumatology ( ACR ) criterion . The clinical diagnosis osteoarthritis ( OA ) confirm American College Rheumatology ( ACR ) clinical radiographic criterion classification idiopathic osteoarthritis ( OA ) knee base upon follow criterion : 1 . Knee pain least 14 day per month 3 month screen 2 . Osteophytes ( radiographic evidence ) 3 . At least 1 follow 3 condition : Age great 50 , Morning stiffness le 30 minute , Crepitus Have Kellgren Lawrence grade I , II , III IV Have mean score least 4 ( moderate ) less equal 8 ( moderatesevere ) 24hour average pain score ( 010 ) ( question 1 ) patient ediary screening randomization knee joint walking Discontinued use analgesic medication ( include overthecounter [ OTC ] analgesics/NonSteroidal AntiInflammatory Drug [ NSAID ] ) least 2 week prior randomization ( patient allow limited use analgesic medication ) Are currently enrol , complete discontinue within last 3 month , clinical trial involve offlabel investigational drug device concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2828360 , related compound component formulation Have abnormality 12lead electrocardiogram ( ECG ) screening , opinion investigator , increase risk associate participation study Have recent current history cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have current previous ( within past year ) Axis 1 diagnosis major depressive disorder , mania , bipolar disorder , psychosis , dysthymia , generalize anxiety disorder , alcohol eating disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision , criterion , determine investigator confirm MiniInternational Neuropsychiatric Interview Are judge Principal Investigator clinically suicidal risk base upon clinical interview Have intercurrent illness clinically significant adverse event Have increase risk seizure evidence history seizure , stroke , surgery cerebral cortex , head trauma loss consciousness Have alanine aminotransaminase ( ALT ) great 2.5 time Upper Limit Normal ( ULN ) Screening , base reference range local laboratory . Moderate great hepatic impairment Have prior renal transplant , current renal dialysis severe renal insufficiency , serum creatinine laboratory value great 1.5 time Upper Limit Normal , base reference range local laboratory Have clinically significant abnormal neurological examination , especially evidence tremor nystagmus Have history symptom suggestive sleep apnoea Use know strong inducer inhibitor Cytochrome P450 within 30 day prior enrolment . Regularly use know drug abuse and/or show positive finding urinary drug screen Have positive alcohol breath test Screening Show evidence human immunodeficiency virus infection and/or positive human HIV antibody Have active malignancy type history malignancy ( except basal cell carcinoma skin excise prior study start ) Are high risk infection Have autoimmune disorder Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate child bearing Use prescription herbal medication safely discontinue end screen Have donate blood 500 milliliter ( mL ) within last 3 month Have average weekly alcohol intake exceed 21 unit per week ( male age 65 ) 14 unit per week ( male 65 female ) , unwilling refrain alcohol consumption duration study Are persons previously receive investigational product study , complete withdrawn study study investigation LY2828360 Are take excluded medication ( analgesic medication ) overthe counter medication discontinue screen Show evidence prior history significant active neurological psychiatric disease include depression Exclusion Disease Criteria : Have secondary cause arthritis knee include septic arthritis , inflammatory joint disease , articular fracture , major dysplasia congenital abnormality , ochronosis , acromegaly , hemochromatosis , Wilson 's disease , primary osteochondromatosis Have low extremity surgery ( include arthroscopy index knee ) within 6 month prior Screening surgery plan index knee anytime Have significant prior injury index knee within 12 month prior Screening Use low extremity assistive device cane knee brace ( use 'shoe lift ' permit ) . Are nonambulatory require use crutch walker . Use cane hand opposite index knee acceptable Have confound painful condition may interfere assessment index joint , i.e. , knee Have musculoskeletal arthritic condition may affect interpretation clinical efficacy and/or safety data otherwise contraindicate participation clinical study Have use corticosteroid prior baseline Have receive hyaluronan injection index knee within previous 6 month prior Treatment Phase day 3 Have initiate change establish physiotherapy program within 2 week prior Treatment Phase day 3 study period An establish physiotherapy program may continue throughout study period unchanged frequency intensity Has prior synovial fluid analysis show White Blood Cell ( WBC ) great equal 2000 cubic millimeter ( mm^3 ) indicative diagnosis OA Have start recently change dose regimen OA specific therapy ( i.e. , nutraceutical product )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis , knee pain , osteoarthritic knee pain</keyword>
</DOC>